$ANVS News
Last published 2d ago
- 2d agoANVSAnnovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board ChairmanGlobeNewswireAnnovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through the pivotal Phase 3 Alzheimer’s data readout in March 2027 MALVERN, Pa.,
- 6d agoANVSAnnovis Announces Pricing of $21.0 Million Public OfferingGlobeNewswireMALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
- 1w agoANVSAnnovis Announces Launch of Proposed Public OfferingGlobeNewswireMALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
- 1w agoANVSAnnovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSEGlobeNewswireMALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
- 1w agoANVSAnnovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026GlobeNewswireMALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
- 2w agoANVSAnnovis to Attend the CTAD 2026 with Three PresentationsGlobeNewswireMALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
- 2mo agoANVSAnnovis Corporate Update Webinar + Q&A - ANNOVIS BIO INCEarnings Call TranscriptsGood afternoon, everyone. Welcome. Thank you for joining today. My name is Brooke, and I'm delighted to welcome you to the Inovis webinar. Today, we will provide the company's update and answer questions from the audienc
- 2mo agoANVSAnnovis Corporate Update Webinar + Q&A - ANNOVIS BIO INCEarnings Call TranscriptsGood afternoon, everyone. Welcome. Thank you for joining today. My name is Brooke, and I'm delighted to welcome you to the Inovis webinar. Today, we will provide the company's update and answer questions from the audienc
- 2mo agoANVSAnnovis to Host Corporate Update Webinar on September 2, 2026GlobeNewswireMALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
- 2mo agoANVSAnnovis Provides Corporate Updates and Second Quarter 2026 Financial ResultsGlobeNewswirePivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients
- 4mo agoANVSAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s DiseaseGlobeNewswirePivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA
- 4mo agoANVSAnnovis Appoints Cheng Fang, Ph.D., as Chief Scientific OfficerGlobeNewswireMALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
- 5mo agoANVSAnnovis Bio Regains NYSE Listing ComplianceGlobeNewswireMALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 5mo agoANVSAnnovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying WarrantsGlobeNewswireMALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 5mo agoANVSAnnovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying WarrantsGlobeNewswireMALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 6mo agoANVSAnnovis Provides Corporate Updates and Reports First Quarter 2026 Financial ResultsGlobeNewswirePhase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New Drug Application (NDA)
- 6mo agoANVSAnnovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026GlobeNewswireMALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 6mo agoANVSAnnovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature PortfolioGlobeNewswireBuntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in
- 7mo agoANVSAnnovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA SubmissionGlobeNewswireFinancing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer's disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28% enrolled
- 7mo agoANVSAnnovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying WarrantsGlobeNewswireMALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 7mo agoANVSARQTAVAINTLA+1The Credibility Filter Wall Street Uses to Sort Biotech WinnersGlobeNewswireVANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid
- 7mo agoANVSAnnovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain InfectionsGlobeNewswireMALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 7mo agoANVSAnnovis Publishes Historical Review of Buntanetap in The ScientistGlobeNewswireMALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 8mo agoANVSAnnovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial ResultsGlobeNewswireMALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 8mo agoANVSAnnovis Announces Two Presentations at the AD/PD™ 2026 International ConferenceGlobeNewswireMALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 9mo agoANVSAnnovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's DiseaseGlobeNewswireMALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
- 10mo agoANVSAnnovis Announces Open-Label Extension Study for Parkinson's Disease PatientsGlobeNewswireEnrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS)
- 11mo agoANVSAnnovis to Host Corporate Update Webinar on January 28, 2026GlobeNewswireMALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases
- 11mo agoANVSAnnovis To Present at the 2025 Annual Meeting of the Parkinson Study GroupGlobeNewswireMALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases
- 11mo agoANVSAnnovis Announces Two Presentations at the CTAD 2025 ConferenceGlobeNewswireMALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases
- 11mo agoANVSAVAINTLARXRX+1Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033GlobeNewswireMarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on
- 11mo agoANVSAnnovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease StudyGlobeNewswireMALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases
- 11mo agoANVSAnnovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's PatientsGlobeNewswireBuntanetap significantly improves cognition in all Parkinson's patients, with those exhibiting Alzheimer's co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers
- 12mo agoANVSAnnovis Provides Corporate Updates and Reports Third Quarter 2025 Financial ResultsGlobeNewswireMALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for
- 1y agoANVSAnnovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's ProgramGlobeNewswireAll 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached the 6-month treatment milestone The study is now 25% complete, keeping Annovis on
- 1y agoANVSAnnovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE RulesGlobeNewswireMALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases
- 1y agoANVSAnnovis Announces $6 Million Registered Direct Offering of Common StockGlobeNewswireMALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases
- 1y agoANVSAnnovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying TreatmentGlobeNewswireMALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases
- 1y agoANVSTRAWAnnovis Appoints Mark Guerin as Chief Financial OfficerGlobeNewswireMALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc.
- 1y agoANVSAnnovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal BuntanetapGlobeNewswireMALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative
- 1y agoANVSAnnovis to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireMALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative
- 1y agoANVSAnnovis Provides Corporate Updates and Reports Second Quarter 2025 Financial ResultsGlobeNewswireMALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative
- 1y agoANVSAnnovis Completes Full Patent Transfer to Crystal BuntanetapGlobeNewswireAnnovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families. All
- 1y agoANVSAnnovis to Attend the AAIC 2025 with Four Poster PresentationsGlobeNewswireMALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative
- 1y agoANVSAnnovis Announces NYSE Acceptance of Plan to Regain Listing ComplianceGlobeNewswireMALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative
- 1y agoANVSAnnovis to Host Webinar and Live Q&A on June 24, 2025GlobeNewswireMALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative
- 1y agoANVSAnnovis Provides Corporate Updates and Reports First Quarter 2025 Financial ResultsGlobeNewswireMalvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative
- 1y agoANVSAnnovis Bio Appoints Hui Liu as Director of BiostatisticsGlobeNewswireMALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for
- 1y agoANVSAnnovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSEGlobeNewswireMALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative
- 1y agoANVSAnnovis to Attend AD/PD™ 2025 with Extensive Scientific ProgramGlobeNewswireMALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as